[46] T. Kröber, A. Knöchlein, K. Eisold, B. Kalbfuß-Zimmermann, and U. Reichl, “Dna

depletion by precipitation in the purification of cell culture-derived influenza vac-

cines,” Chem. Eng. Technol., vol. 33, no. 6, pp. 941–959, 2010.

[47] A. T. Hanke and M. Ottens, “Purifying biopharmaceuticals: Knowledge-based

chromatographic process development,” Trends Biotechnol., vol. 32, no. 4,

pp. 210–220, 2014.

[48] M. Mellado and C. Peixoto, “Ultrafiltration and Diafiltration of Adenovirus serotype

5 with Sartocon® Slice cassettes installed within a SARTOFLOW ® Smart benchtop

crossflow system application note,” 2017.

[49] B. Carvalho et al., “Membrane – Based Approach for the Downstream Processing of

In fl uenza Virus – Like Particles,”Biotechnol. J. vol. 1800570, pp. 1–12, 2019.

[50] G. E. Healthcare and L. Sciences, “Concentration and diafiltration of cell-derived,

live influenza virus using 750 C hollow fiber filter cartridge,”

[51] K. Marino and P. Levison, “Achieving Process Intensification with Single-Pass

TFF,” Genet. Eng. Biotechnol. News, vol. 37, no. 15, pp. 30–31, Aug. 2017.

[52] M. Zhao, M. Vandersluis, J. Stout, U. Haupts, M. Sanders, and R. Jacquemart,

“Affinity chromatography for vaccines manufacturing: Finally ready for prime

time?,” Vaccine, vol. 37, no. 36, pp. 5491–5503, Apr. 2018.

[53] K. M. Łącki and F. J. Riske, “Affinity Chromatography: An Enabling Technology

for Large-Scale Bioprocessing,” Biotechnol. J., vol. 15, no. 1, pp. 1–11, 2020.

[54] T. Weigel, T. Solomaier, A. Peuker, T. Pathapati, M. W. Wolff, and U. Reichl, “A

flow-through chromatography process for influenza A and B virus purification,”

J. Virol. Methods, vol. 207, pp. 45–53, Oct. 2014.

[55] M. W. Wolf and U. Reichl, “Downstream processing of cell culture-derived virus

particles,” Expert Rev. Vaccines, vol. 10, no. 10, pp. 1451–1475, Oct. 2011.

[56] Sartorius Stedim Biotech GmbH, “Optimizing adenovirus purification processes,”

2017.

[57] S. B. Carvalho et al., “Purification of influenza virus-like particles using sulfated

cellulose membrane adsorbers,” J. Chem. Technol. Biotechnol., vol. 93, no. 7,

pp. 1988–1996, 2018.

[58] S. Tinch, K. Szczur, W. Swaney, L. Reeves, and S. R. Witting, “A scalable lentiviral

vector production and purification method using mustang Q chromatography and

tangential flow filtration,” Methods Mol. Biol., vol. 1937, pp. 135–153, 2019.

[59] D. Vincent et al., “The development of a monolith-based purification process for

Orthopoxvirus vaccinia virus Lister strain,” J. Chromatogr. A, vol. 1524, pp. 87–100,

2017.

[60] L. M. Fischer, M. W. Wolff, and U. Reichl, “Purification of cell culture-derived

influenza A virus via continuous anion exchange chromatography on monoliths,”

Vaccine, vol. 36, no. 22, pp. 3153–3160, 2018.

[61] N. K. Jain, N. Sahni, O. S. Kumru, S. B. Joshi, D. B. Volkin, and C. Russell

Middaugh, “Formulation and stabilization of recombinant protein based virus-like

particle vaccines,” Adv. Drug Deliv. Rev., vol. 93, pp. 42–55, 2015.

[62] T. J. Moyer et al., Engineered immunogen binding to alum adjuvant enhances

humoral immunity, vol. 26, no. 3. 2020.

[63] M. M. E. Sunay et al., “Glucopyranosyl lipid adjuvant enhances immune response to

Ebola virus-like particle vaccine in mice,” Vaccine, vol. 37, no. 29, pp. 3902–3910,

2019.

[64] G.-A. Junter and L. Lebrun, “Polysaccharide-based chromatographic adsorbents for

virus purification and viral clearance,” J. Pharm. Anal., vol. 10, no. 4,

pp. 291–312,2020.

198

Bioprocessing of Viral Vaccines